Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 severe or critically meta-analysis

COV-BARRIER (critically ill)
  NCT04421027		 RCTbaricitinibplaceboCOVID-19 severe or criticallylow
51/50 suggested
  • suggested 46 % decrease in deaths,death D28 with a high degree of certainty due to low risk of bias
  • suggested 1.9-fold increase in clinical improvement with a high degree of certainty due to low risk of bias
Cao RCTruxolitinibvitamin CCOVID-19 severe or criticallysome concern
21/21 suggested
  • suggested 4.5-fold increase in radiologic improvement (14-day) with a moderate degree of certainty due to some concern in risk of bias
2 studies excluded by filtering options (1 RCT / 1 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons